Get the Stockscreener App
6.25
9.46%
0.54
Galectin Therapeutics Inc stock is traded at $6.25, with a volume of 760.30K.
It is up +9.46% in the last 24 hours and up +7.20% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$5.71
Open:
$5.72
24h Volume:
760.30K
Relative Volume:
1.90
Market Cap:
$402.95M
Revenue:
-
Net Income/Loss:
$-45.08M
P/E Ratio:
-8.5616
EPS:
-0.73
Net Cash Flow:
$-33.68M
1W Performance:
+8.89%
1M Performance:
+7.20%
6M Performance:
+366.42%
1Y Performance:
+214.07%
1-Day Range:
$5.54
$6.40
1-Week Range:
$5.10
$6.40
52-Week Range:
$0.726
$6.66
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
6.25 | 368.14M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Market Pulse: Will Galectin Therapeutics Inc stock benefit from AI adoptionJuly 2025 Sentiment & Daily Stock Trend Watchlist - moha.gov.vn
Galectin therapeutics director sells shares worth $1.05 million By Investing.com - Investing.com Canada
Galectin Therapeutics (NASDAQ:GALT) Director Sells $105,273.30 in Stock - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Director Sells $950,820.00 in Stock - MarketBeat
Galectin therapeutics director sells shares worth $1.05 million - Investing.com India
Galectin Therapeutics Insider Sold Shares Worth $1,055,311, According to a Recent SEC Filing - marketscreener.com
Dir Shlevin Sells 175,790 ($1.1M) Of Galectin Therapeutics Inc [GALT] - TradingView — Track All Markets
There is no way Galectin Therapeutics Inc (GALT) can keep these numbers up - Setenews
Galectin Therapeutics shareholders elect board members and approve key proposals By Investing.com - Investing.com Nigeria
10x fund sells Galectin Therapeutics (GALT) shares worth $920,855 By Investing.com - Investing.com Australia
10x fund sells Galectin Therapeutics (GALT) shares worth $920,855 - Investing.com
Galectin Therapeutics : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - marketscreener.com
Galectin Therapeutics shareholders elect board members and approve key proposals - Investing.com
Galectin Therapeutics (NASDAQ:GALT) Major Shareholder Fund L.P. 10X Sells 30,000 Shares - MarketBeat
Prepare Yourself for Liftoff: Galectin Therapeutics Inc (GALT) - Setenews
How Galectin Therapeutics Inc. (PHPN) stock reacts to Fed tighteningJuly 2025 Volume & Daily Growth Stock Tips - Newser
Is Galectin Therapeutics Inc. (PHPN) stock a contrarian opportunityBear Alert & Safe Capital Growth Stock Tips - Newser
10x fund sells Galectin therapeutics (GALT) shares worth $851,700 By Investing.com - Investing.com Canada
10x fund sells Galectin therapeutics (GALT) shares worth $851,700 - Investing.com
Will Galectin Therapeutics Inc. (PHPN) stock benefit from commodity supercycleJuly 2025 Rallies & Short-Term High Return Strategies - Newser
Clinical Progress Drives Galectin Shares Up Post-NAVIGATE Data (NASDAQ:GALT) - Seeking Alpha
Is Galectin Therapeutics Inc. (PHPN) stock a buy on weaknessWeekly Trade Review & Community Consensus Stock Picks - Newser
Is Galectin Therapeutics Inc. (PHPN) stock undervalued historicallyQuarterly Risk Review & High Win Rate Trade Alerts - Newser
Will Galectin Therapeutics Inc. (PHPN) stock rise with strong economy2025 Stock Rankings & Growth Oriented Trading Recommendations - Newser
Can Galectin Therapeutics Inc. (PHPN) stock double in coming yearsQuarterly Profit Report & Daily Growth Stock Tips - Newser
Galectin Therapeutics Reveals Promising NAVIGATE Trial Results - TipRanks
Galectin Therapeutics Inc Presents NAVIGATE Trial Results - TradingView — Track All Markets
Will Galectin Therapeutics Inc. (PHPN) stock sustain bullish trend into 2025Quarterly Growth Report & High Accuracy Investment Entry Signals - Newser
Will Galectin Therapeutics Inc. (PHPN) stock beat international competitionJuly 2025 Snapshot & Stepwise Entry/Exit Trade Alerts - Newser
How big funds are accumulating Galectin Therapeutics Inc. (PHPN) stockMarket Activity Report & Weekly Chart Analysis and Guides - Newser
Why Galectin Therapeutics Inc. stock is favored by pension fundsJuly 2025 Review & Free Technical Confirmation Trade Alerts - BỘ NỘI VỤ
Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200 Day Moving AverageTime to Sell? - MarketBeat
The growth track for Galectin Therapeutics Inc (GALT) has changed recently - setenews.com
Will Galectin Therapeutics Inc. stock sustain high P E ratiosTrade Volume Summary & Weekly High Potential Alerts - BỘ NỘI VỤ
Galectin Therapeutics: NAVIGATE Data Validates The Fibrosis Thesis - Seeking Alpha
Wealthspire Advisors LLC Buys 81,144 Shares of Galectin Therapeutics Inc. $GALT - MarketBeat
How Galectin Therapeutics Inc. stock reacts to Fed rate cutsDip Buying & Stepwise Trade Execution Plans - newser.com
How Galectin Therapeutics Inc. (PHPN) stock trades pre earnings2025 Support & Resistance & Fast Entry Momentum Trade Alerts - newser.com
What sentiment indicators say about Galectin Therapeutics Inc. stockTrade Analysis Summary & Real-Time Buy Zone Alerts - newser.com
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):